Of the 157 patients, 121 were tested for KRAS in tumor and cfDNA samples; 61 (50%) patients had KRAS G12 or 13 mutations in the FFPE tumor samples and 57 (47%) had KRAS mutations in cfDNA from plasma with overall agreement between testing in 101 (83%) cases (kappa = 0.67, SE 0.07, 95% CI 0.54–0.80) with sensitivity 80% (95% CI 0.68–0.89), specificity 87% (95% CI 0.75–0.94), positive predictive value 86% (95% CI 0.74–0.94) and negative predictive value 81% (95% CI 0.70–0.90; Table 1). This evidence concerns the gene KRAS and neoplasm.